Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.35 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605681 | 1.00 | CTSS (0.38) | CTSSCTSKCA2MAPK1GPR84 | |
| SCHEMBL4813012 | 1.00 | CTSS (0.38) | CTSSCTSKCA2MAPK1GPR84 | |
| SCHEMBL6605430 | 1.00 | CTSS (0.38) | CTSSCTSKCA2MAPK1GPR84 | |
| SCHEMBL6402824 | 1.00 | CTSS (0.38) | CTSSCTSKCA2MAPK1GPR84 | |
| SCHEMBL6402816 | 1.00 | CTSS (0.38) | CTSSCTSKCA2MAPK1GPR84 | |
| SCHEMBL23496358 | 0.82 | CTSC (0.33) | CTSSCTSK | |
| SCHEMBL6403622 | 0.81 | ACACB (0.36) | — | |
| SCHEMBL19744749 | 0.80 | FOLH1 (0.31) | — | |
| SCHEMBL19744753 | 0.80 | FOLH1 (0.31) | — | |
| SCHEMBL8371558 | 0.79 | CTSK (0.56) | CTSSCTSKCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | disclosed |
| EP-1494663-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SmithKline Beecham Corporation (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086385-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | CTSK, CTSB, CTSD | CTSS 4/4885CTSK 1/4885CA2 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.